(Q51802069)

12 April 2018

title

A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. (English)

1 reference

12 April 2018

main subject

phase II clinical trial

0 references

1 reference

1 reference

3

Antoni Ribas

1 reference

12 April 2018

author name string

Evan M Hersh

1

1 reference

12 April 2018

Steven J O'Day

2

1 reference

12 April 2018

Wolfram E Samlowski

4

1 reference

12 April 2018

Michael S Gordon

5

1 reference

12 April 2018

Deganit E Shechter

6

1 reference

12 April 2018

Alicia A Clawson

7

1 reference

12 April 2018

Rene Gonzalez

8

1 reference

12 April 2018

language of work or name

English

0 references

publication date

1 January 2010

1 reference

12 April 2018

published in

Cancer

1 reference

12 April 2018

volume

116

1 reference

12 April 2018

issue

1

1 reference

12 April 2018

page(s)

155-163

1 reference

12 April 2018

Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer.

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24720

21 January 2018

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24720

7 January 2021

Surgical treatment of metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24720

7 January 2021

Systemic chemotherapy for the treatment of metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24720

7 January 2021

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24720

7 January 2021

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24720

7 January 2021

Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24720

7 January 2021

Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24720

7 January 2021

A phase II study of taxol in patients with malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24720

7 January 2021

A phase II trial of taxol in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24720

7 January 2021

Phase II trial of weekly paclitaxel in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24720

7 January 2021

Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24720

7 January 2021

Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24720

7 January 2021

Albumin-bound paclitaxel: a next-generation taxane

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24720

7 January 2021

Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24720

7 January 2021

Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24720

7 January 2021

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24720

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24720

7 January 2021

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24720

7 January 2021

Transcytosis of plasma macromolecules in endothelial cells: a cell biological survey.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24720

7 January 2021

Distribution of SPARC in normal and neoplastic human tissue

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24720

7 January 2021

Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24720

7 January 2021

SPARC and tumor growth: where the seed meets the soil?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24720

7 January 2021

Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24720

7 January 2021

Formulating paclitaxel in nanoparticles alters its disposition

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24720

7 January 2021

Identifiers

DOI

10.1002/CNCR.24720

1 reference

12 April 2018

1 reference

12 April 2018